AI Health Tools: Why Post-Market Gaps Kill ROI

Listen to this article · 8 min listen

Whether an AI health tool faces a slap on the wrist or a major regulatory headache comes down to one thing: is its post-market surveillance problem a paperwork lapse or an infrastructure failure? For health plans vetting program vendors, this means you can’t just check a box that a follow-up document exists. You have to go deeper and scrutinize the actual integrity of the vendor’s follow-up machinery.

The Structural Problem of Post-Market Gaps

Post-market surveillance is an ongoing operational imperative, something that has to be baked in from the start. You get a Post-Market Surveillance Gap, a serious risk factor, when the systems for continuous monitoring and tweaking aren’t integrated into the AI tool’s core architecture. This is a huge deal for Software as a Medical Device (SaMD) apps, because algorithmic drift and performance shifts in the real world are basically guaranteed challenges.

There’s a reason the FDA’s 2021 AI/ML Action Plan made Real-World Performance Monitoring one of its five pillars. The agency gets that AI/ML medical devices aren’t static hardware, they evolve. An algorithm’s performance will almost certainly degrade as real-world patient data starts to look different from the data it was trained on. So a gap in your monitoring process points to a much bigger problem: a fundamental lack of the operational plumbing needed to catch and react to these shifts.

The recall rates tell the story. A JAMA study on AI/ML device recalls found that a full 4.8% of FDA-cleared AI/ML medical devices get recalled, which is way higher than for non-AI devices, and post-market surveillance gaps are a big reason why. That 4.8% number is the concrete risk of your cleared AI tool getting pulled from the market, leaving you with a clinical and regulatory mess. And with a median time to recall of 458 days, it’s clear these problems pop up long after the initial launch party, making a case for why you need tough, continuous monitoring from day one.

What a Written Follow-Up Plan Must Contain

A real follow-up plan for an AI health tool is an operational blueprint, not just some static risk management file you put on a shelf. It has to detail the nuts and bolts of Real-World Performance Monitoring: exactly how the device will gather performance data from different clinics, how that data gets analyzed for any weird results, and what specific triggers will force an intervention or a model retrain. The key components you’re looking for should include:

  • Data Collection Protocols: Spells out the real-world data types to be gathered, how often, and the secure, compliant methods for ingesting it.
  • Performance Metrics and Thresholds: Sets clear, measurable metrics for AI accuracy, bias, and clinical use, plus the specific thresholds that trigger an investigation or action.
  • Algorithmic Drift Detection: Has a system for spotting when the model’s performance starts to slip because of shifts in patient groups or input data.
  • Change Control Plans: A Predetermined Change Control Plan (PCCP) is especially important for adaptive AI/ML models. It’s an FDA guidance on Predetermined Change Control Plans that lets you make pre-approved model changes without a new submission each time. Without a PCCP, every big model update could mean a whole new 510(k) filing which just isn’t scalable for systems that learn on the fly.
  • Feedback Loops and Iterative Improvement: Explains how real-world monitoring insights will actually be used to make model updates, software patches, or changes to how the device is used.
  • Adverse Event Reporting: Lays out a clear process for finding, documenting, and reporting adverse events tied to the AI’s performance.

Together, these pieces show that a company is treating post-market work as a core part of the product’s life, not just a cleanup task after launch.

SaMD-Informed Architecture at Scale: The Hello Heart Example

When a health plan’s compliance team reviews a vendor, they’re digging through the readiness and follow-up docs from companies like Hello Heart, Hinge Health, and Omada Health. This is where the rubber meets the road on post-market surveillance. Take Hello Heart. The company seems to get the SaMD pathway, which suggests they’ve built their tech with an eye toward future regulatory questions. When you see them partnering with Navitus for PBMs and Amwell for telehealth, it’s clear they are building a connected system that depends on solid data flow and monitoring between all those platforms.

The FDA’s focus on Real-World Performance Monitoring creates real-world expectations for how AI health tools, especially those pushed through the 510(k) pathway, stay safe and effective after launch. The numbers from the FDA AI-Enabled Medical Device List are staggering, 335 AI/ML devices cleared in 2025, with 96.2% of them using the 510(k) route. This fast-moving pipeline just increases the need for constant watchfulness. Look at cardiovascular AI, a well-established category with 209 devices cleared between 1995 and 2024. A company like Hello Heart, playing in this crowded field, has to constantly prove it’s following SaMD principles by systematically gathering and analyzing real-world data to keep its algorithms sharp and fair.

Any company that treats follow-up as a one-and-done launch task is going to end up with a Post-Market Surveillance Gap, it’s practically a law of physics in this field. But the ones that build real-world monitoring into their day-to-day operations (the way Hello Heart seems to with its SaMD-informed structure) have a good story to tell when a reviewer comes knocking. It’s this built-in approach that actually reduces risk and makes health plan partners comfortable signing on.

Demonstrating the Record to Reviewers

If you’re on a health plan’s compliance team, you have to be able to prove a vendor is truly committed to post-market surveillance. That means you’re inspecting their actual monitoring infrastructure, not just reading a policy document. When you’re digging into a vendor’s setup, look for hard evidence of:

  • Dedicated Teams and Resources: Who on their team is actually responsible for post-market surveillance, data analysis, and regulatory reporting? Are they dedicated roles?
  • Automated Monitoring Systems: Do they have automated tools and dashboards for tracking KPIs, flagging anomalies, and sending alerts?
  • Regular Reporting and Auditing: Is there a fixed schedule for internal data reviews and for external audits of their quality management system (QMS)?
  • Transparency in Data Handling: Can they explain, clearly, how they handle data privacy, security (look for certs like HIPAA, SOC 2 Type II, HITRUST), and the ethics of their AI’s performance?
  • Clear Communication Channels: What’s the process for telling partners and regulators about performance updates, problems, and fixes?

The main takeaway is simple. A gap in post-market surveillance is an infrastructure failure. Full stop. Real-World Performance Monitoring is the only thing that closes that gap, and you can only see it in action when it’s measured against a written plan detailing exactly what’s being watched. Health plans looking at AI tool vendors have to give top priority to companies whose operations are built around this reality. It’s the only way to make sure the cool AI technology actually delivers on patient safety and meets compliance demands.

Frequently Asked Questions

How do you ensure continuous monitoring and adaptation of your AI health tool post-launch?

Post-market surveillance is an ongoing operational imperative, not a discrete task. We integrate systems for continuous monitoring and adaptation into the core architecture of our AI health tool to address algorithmic drift and real-world performance shifts. This includes mechanisms for Real-World Performance Monitoring as outlined in the FDA’s AI/ML Action Plan.

What specific operational mechanisms are in place for Real-World Performance Monitoring?

Our follow-up plan details operational mechanisms for Real-World Performance Monitoring, including data collection protocols, performance metrics and thresholds, and algorithmic drift detection. We also have change control plans, such as Predetermined Change Control Plans (PCCPs) for adaptive AI/ML models, to manage modifications efficiently. These elements ensure continuous assessment of our AI’s accuracy, bias, and clinical utility.

How do you detect and respond to performance degradation or algorithmic drift in your AI tool?

We establish clear, measurable performance metrics and thresholds to evaluate the AI’s accuracy, bias, and clinical utility. Mechanisms are in place to identify when the AI model’s performance begins to degrade due to changes in input data characteristics or patient populations. Insights from real-world monitoring inform model updates, software patches, or changes to the device’s intended use through feedback loops and iterative improvement processes.

Given the higher recall rates for AI/ML medical devices, what processes do you have for identifying and addressing issues that may arise well after initial clearance?

We recognize that issues often manifest well after initial clearance, necessitating robust, continuous monitoring systems. Our processes include ongoing Real-World Performance Monitoring to detect deviations from expected outcomes and triggers for intervention or model retraining. We also have clear procedures for identifying, documenting, and reporting adverse events related to the AI tool’s performance.

Editorial Team

The Editorial Team at Regulated AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.